Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Salvage radiotherapy after prostatectomy - what is the best time to treat?
Siegmann A, Bottke D, Faehndrich J, Brachert M, Lohm G, Miller K, Bartkowiak D, Hinkelbein W, Wiegel T. Siegmann A, et al. Among authors: bartkowiak d. Radiother Oncol. 2012 May;103(2):239-43. doi: 10.1016/j.radonc.2011.10.024. Epub 2011 Nov 25. Radiother Oncol. 2012. PMID: 22119375
Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study.
Siegmann A, Bottke D, Faehndrich J, Lohm G, Miller K, Bartkowiak D, Wiegel T, Hinkelbein W. Siegmann A, et al. Among authors: bartkowiak d. Strahlenther Onkol. 2011 Aug;187(8):467-72. doi: 10.1007/s00066-011-2229-3. Epub 2011 Jul 22. Strahlenther Onkol. 2011. PMID: 21786112
Second cancer after radiotherapy, 1981-2007.
Bartkowiak D, Humble N, Suhr P, Hagg J, Mair K, Polivka B, Schneider U, Bottke D, Wiegel T. Bartkowiak D, et al. Radiother Oncol. 2012 Oct;105(1):122-6. doi: 10.1016/j.radonc.2011.09.013. Epub 2011 Oct 10. Radiother Oncol. 2012. PMID: 21993405
Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.
Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Stöckle M, Rübe C, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K. Wiegel T, et al. Among authors: bartkowiak d. Eur Urol. 2014 Aug;66(2):243-50. doi: 10.1016/j.eururo.2014.03.011. Epub 2014 Mar 21. Eur Urol. 2014. PMID: 24680359 Clinical Trial.
Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow A, Wirth M, Störkel S, Golz R, Engenhart-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K. Wiegel T, et al. Among authors: bartkowiak d. Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):288-94. doi: 10.1016/j.ijrobp.2014.09.039. Epub 2014 Nov 20. Int J Radiat Oncol Biol Phys. 2015. PMID: 25445556 Clinical Trial.
59 results